Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Yazaki
H
H
AIDS Clinical Center, International Medical Center of Japan, Tokyo 162-8655, Japan.
Kikuchi
Y
Y
Oka
S
S
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D003521:Cyclopropanes; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D018454:Spouses; D018119:Stavudine / Q000627:therapeutic use; D013997:Time Factors
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019259:Lamivudine; D018119:Stavudine; C098320:efavirenz